6HV1 Stock Chart & Stats
€4.40
€0.10(2.33%)
At close: 4:00 PM EDT
€4.40
€0.10(2.33%)
Day’s Range― - ―
52-Week Range€1.01 - €9.35
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€384.24M
Enterprise Value€198.17
Total Cash (Recent Filing)€120.27M
Total Debt (Recent Filing)€1.11M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Sep 10, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding96,292,330
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.31Price Target Upside66.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.56
Revenue Forecast (FY)€2.49M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetVery low debt reduces near-term refinancing risk and gives strategic financial flexibility to prioritize R&D or partnerships. For a development-stage biotech, minimal leverage lowers fixed obligations and preserves options to time future financings or collaborations.
Positive Phase 3 UpLIFT Interim ResultsRobust interim efficacy and an absence of drug-related adverse events in a pivotal Phase 3 cohort strengthen the clinical case for ersodetug in tumor hyperinsulinism. Durable clinical validation increases the program's development value and improves long-term approval and adoption prospects in a high-need niche.
Active FDA Engagement On SunRIZE DataConstructive regulatory dialogue—FDA acknowledgement of endpoint challenges and a request for a comprehensive submission—signals a defined pathway to resolve issues. This reduces structural regulatory uncertainty and supports a focused strategy toward potential approval.
Bears Say
Accelerating Cash BurnSubstantially negative and worsening free cash flow indicates heavy ongoing cash consumption to fund trials. Over 2–6 months this increases the probability management must raise capital, which can dilute shareholders and constrain discretionary investment in pipeline expansion or commercialization readiness.
Pre-revenue, Development-stage ModelAbsence of product revenue means operating funding depends on external financings or partnerships. This structural dependence heightens financing risk and ties program progress to capital markets or deal activity rather than internal cash generation, limiting resilience to setbacks.
Negative Returns And Eroding Equity BaseDeeply negative returns on equity and a shrinking equity base reflect capital consumption and weaken the firm’s buffer against trial setbacks. Structurally, this raises the probability of dilutive financing and reduces financial resilience during multi-year development cycles.
Rezolute News
6HV1 FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was €1.01 and its highest was €9.35 in the past 12 months.
What is Rezolute’s market cap?
Rezolute’s market cap is €384.24M.
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Sep 10, 2026 which is in 21 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on May 12, 2026. The company reported -€0.137 earnings per share for the quarter, beating the consensus estimate of -€0.155 by €0.018.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -0.13.
How many shares outstanding does Rezolute have?
Rezolute has 96,292,330 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -€0.137 in its last earnings report, beating expectations of -€0.155. Following the earnings report the stock price went up 4.585%.
Which hedge fund is a major shareholder of Rezolute?
Currently, no hedge funds are holding shares in DE:6HV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rezolute Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€7.31 (66.22% Upside)
€7.31 (66.22% Upside)
Blogger Sentiment
Neutral
DE:6HV1 Sentiment 50%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
32.43%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
6HV1 Stock 12 Month Forecast
Average Price Target
€7.31
▲(66.22% Upside)